Humanized III-type collagen engineering bacteria, carrier, preparation method and application
By modifying the Pichia pastoris engineered strain GS115-pPIC9K-COL3A1, constitutive expression and high-pressure homogenization techniques were employed to solve the problems of protease degradation and methanol induction in humanized type III collagen. This enabled the preparation of high-purity collagen and the reuse of waste bacterial cells, resulting in strong cell repair and firming/anti-wrinkle effects.
Patent Information
- Application Number
- CN202410810221.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-21
- Publication Date
- 2024-11-08
AI Technical Summary
Existing technologies for expressing humanized type III collagen suffer from protease degradation and methanol induction risks, and the ability of collagen to promote cell migration and repair is insufficient.
Using the modified Pichia pastoris engineered strain GS115-pPIC9K-COL3A1, high-purity humanized type III collagen was prepared by replacing methanol induction with a constitutive expression mode and combining computer-aided optimization screening of amino acid fragments that resist degradation and promote cell migration and repair. The waste cells were then treated with high-pressure homogenization technology to prepare fermentation lysate filtrate.
It achieves efficient and safe collagen expression with a collagen purity of over 98.0%, possesses strong cell repair capabilities and significant firming and anti-wrinkle effects, reduces production costs, and enables the secondary utilization of waste microbial cells.
Smart Images

Figure CN118909812A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of bioengineering technology, relates to humanized type III collagen engineering bacteria, and also relates to a preparation method of the engineering strain. The present invention also relates to a method for preparing humanized type III collagen using the engineering strain and its application. The present invention also relates to preparing Pichia pastoris fermentation lysate filtrate using discarded bacteria of the engineering strain, a preparation method and its application. Background Art
[0002] The field of humanized collagen is an emerging industry in the market in recent years. It is mostly prepared using genetic engineering methods, and research mainly focuses on types I and III.
[0003] At present, the expression of humanized type III collagen by various enterprises and research institutions mainly has the following strategies: ① Based on the a1 chain of natural human type III collagen, the core domain is intercepted for n-repeated expression; ② The core domain is intercepted and multiple fragments are spliced for expression; ③ The core domain is intercepted, multiple fragments are spliced, and the spliced sequence is used as a monomer for n-repeated expression; ④ Large fragments are intercepted for expression. Pichia pastoris is favored by all parties because of its clear exocrine pathway, single genetic background, convenient purification, and partial modification of the expression product. According to the publicly available information, well-known enterprises in this field, such as Shanxi A Company, Shaanxi B Company, Jiangsu C Company, Jiangsu D Company, Guangzhou E Company, etc., all adopt one of the first three strategies. Shanxi Company A and Shaanxi Company B mainly use Escherichia coli as chassis cells for the fermentation and production of humanized collagen; Jiangsu Company C, Jiangsu Company D and Guangzhou Company E mainly use Pichia pastoris chassis cells for the fermentation and production of humanized collagen, and all of them mainly use the conventional pPIC9K exocrine pathway, which requires the large-scale use of methanol, a toxic and harmful substance, to induce production. The company's collagen-related patents from 2010 to 2022, such as the invention patent with application number 201010527766.7 "Genetically recombinant human collagen fusion peptides and their preparation methods and applications", the invention patent with application number CN201210139088.6 "Type I human collagen and epidermal growth factor dual expression vector and its expression and purification method", the invention patent with application number CN201610388271.8 "A recombinant human collagen and its encoding gene and preparation method", etc. The collagen produced is also produced using the Pichia pastoris pPIC9K exocrine pathway and methanol induction.
[0004] During the expression and production process of humanized collagen, protein degradation is inevitable, especially for high molecular weight collagen, which is more easily degraded by proteases produced by chassis cells during the expression process. This is the key point that all companies must face and break through in the process of preparing humanized collagen. In addition, the ability of humanized collagen to promote cell migration and repair is also a focus of attention. Stronger ability to promote cell migration often means stronger cell repair ability and stronger efficacy. Summary of the invention
[0005] The purpose of the present invention is to provide an engineered Pichia pastoris capable of producing humanized type III collagen, thereby solving the problem of use risk or residue caused by the introduction of methanol in the protein expression process of the prior art.
[0006] The second object of the present invention is to provide a method for preparing the above-mentioned humanized type III collagen by using Pichia pastoris engineered bacteria.
[0007] The third object of the present invention is to provide a method for preparing humanized type III collagen by using the above-mentioned Pichia pastoris engineered bacteria for humanized type III collagen.
[0008] The fourth object of the present invention is to provide the application of the above-mentioned humanized type III collagen in the fields of beauty and skin care, high-end medical beauty products and medical devices.
[0009] The fifth object of the present invention is to provide a Pichia pastoris fermentation lysate filtrate prepared by using the discarded bacterial cells of the Pichia pastoris engineered bacteria producing the humanized type III collagen.
[0010] The sixth object of the present invention is to provide a method for preparing Pichia pastoris fermentation lysate filtrate by using the discarded bacterial bodies of the Pichia pastoris engineered bacteria producing the humanized type III collagen.
[0011] The seventh objective of the present invention is to provide the application of the above-mentioned Pichia yeast fermentation lysate filtrate in the field of beauty and skin care, and high-end medical beauty products.
[0012] The first technical solution adopted by the present invention is a humanized type III collagen engineering bacterium, the humanized type III collagen engineering bacterium is GS115-pPIC9K-COL3A1, belongs to Pichia pastoris, and the strain is deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration, with a deposit number of CGMCC No: 30003 and a deposit date of March 11, 2024;
[0013] The engineered bacteria GS115-pPIC9K-COL3A1 was obtained by transforming the expression vector pPIC9K-COL3A1 into the original strain of Pichia pastoris GS115.
[0014] The present invention is also characterized in that:
[0015] The humanized type III collagen, the amino acid sequence is shown in SEQ ID No.1, and the nucleotide sequence is shown in SEQ ID No.2.
[0016] The amino acid sequence of humanized type III collagen is selected from 315-338aas, 354-374aas, 429-452aas, 459-476aas, 501-527aas, 540-575aas, 582-613aas, 647-686aas, 882-908aas, 921-944aas, 1023-1046aas, 1056-1094aas, 1161-1199aas on the a1 chain of full-length humanized type III collagen, and is spliced in sequence from N-terminus to C-terminus to obtain a combined peptide chain of 375 amino acids.
[0017] The specific method for obtaining the expression vector pPIC9K-COL3A1 is as follows:
[0018] The pPIC9K vector was selected, and the Xho I site at 5708 bp was mutated from CTCGAG to CACGAG to obtain a point mutation pPIC9K vector;
[0019] The original strain of Pichia pastoris GS115 numbered CICC 33158 was selected, and the nucleotide sequence of 600 bp upstream of the aat promoter in the original strain and the Pichia pastoris a-Factor signal peptide sequence were spliced to form a grafted aat promoter, the sequence of which is shown in SEQ ID No. 3; a Pme I restriction endonuclease site was added to the 5' end of the sequence shown in SEQ ID No. 3, and an Xho I restriction endonuclease cleavage site was added to the 3' end, and the grafted aat promoter and the point-mutated pPIC9K vector were double-digested with Pme I and Xho I, respectively, and then connected to transform Escherichia coli for screening to obtain the modified pPIC9K vector;
[0020] An Xho I restriction endonuclease site was added to the 5' end of the sequence shown in SEQ ID No. 2, and an EcoR I restriction endonuclease site was added to the 3' end to obtain a COL3A1 nucleotide sequence, and the COL3A1 nucleotide sequence was fully synthesized; the fully synthesized COL3A1 nucleotide sequence and the modified pPIC9K vector were double-digested with Xho I and EcoR I, respectively, to obtain COL3A1 / X+E and modified pPIC9K / X+E, and then the two were connected and transformed into Escherichia coli competent cells, and the pPIC9K-COL3A1 expression vector was constructed and screened.
[0021] The second technical solution adopted by the present invention is a method for preparing humanized type III collagen engineering bacteria. The engineering bacteria GS115-pPIC9K-COL3A1 is obtained by transforming the pPIC9K-COL3A1 vector into the original strain of Pichia pastoris GS115, and screening by histidine deficiency and G418 antibiotic screening. The specific method is as follows:
[0022] The obtained pPIC9K-COL3A1 plasmid was linearized with restriction endonuclease Sal I to obtain a pPIC9K-COL3A1 linearized plasmid, and the pPIC9K-COL3A1 linearized plasmid was transformed into Pichia pastoris GS115 competent cells, and histidine deficiency screening and 4 mg / mL G418 antibiotic screening were performed to obtain a positive clone GS115-pPIC9K-COL3A1 engineering strain;
[0023] The obtained GS115-pPIC9K-COL3A1 engineered strain was inoculated into BMGY medium for a shake flask experiment, glycerol was added, and it was naturally grown and expressed. The shake flask supernatant was collected for SDS-PAGE electrophoresis detection to screen out the GS115-pPIC9K-COL3A1 engineered bacteria that highly expressed humanized type III collagen.
[0024] The third technical solution adopted by the present invention is a method for preparing humanized type III collagen, wherein the humanized type III collagen is obtained by fermentation expression and purification of the above-mentioned engineering bacteria GS115-pPIC9K-COL3A1, and the specific steps are as follows:
[0025] S1: protein fermentation: the GS115-pPIC9K-COL3A1 engineered strain was inoculated into BMGY medium for high-density fermentation, supplemented with glycerol culture, and the supernatant was retained after the fermentation to obtain the fermentation supernatant containing humanized type III collagen;
[0026] S2: Ultrafiltration concentration: Take the fermentation supernatant, centrifuge to remove the bacteria, filter using a 0.22um hollow fiber ultrafiltration membrane filter, ultrafiltration concentrate the supernatant to 20% of the original volume, remove inorganic salts in the ultrafiltration concentrate by gel filtration to obtain a desalted solution;
[0027] S3: treating the desalted liquid by ion exchange chromatography, collecting the eluate in sections and concentrating it;
[0028] S4: freeze-drying to obtain freeze-dried humanized type III collagen powder with a purity greater than 98.0%.
[0029] The present invention is also characterized in that:
[0030] The specific method of S1 is: the screened GS115-pPIC9K-COL3A1 engineered strain was inoculated into BMGY medium and cultured at 30°C with shaking until the OD 600 When the pH reaches 9.8-10.3, the culture medium is transferred to a fermentation tank filled with FBS culture medium, the temperature is kept constant at 28-30°C, the pH value is adjusted to 5.0-6.0 with ammonia water, the dissolved oxygen is controlled at 20-30%, and the fermentation is carried out for 90-100 hours. After the fermentation is completed, the fermentation broth is separated into solid and liquid by centrifugation, and the supernatant is retained to obtain the supernatant containing the target protein humanized type III collagen.
[0031] The fourth technical solution adopted by the present invention is humanized type III collagen, which can be applied to the fields of beauty and skin care, high-end medical beauty products and medical devices.
[0032] The fifth technical solution adopted by the present invention is that the Pichia pastoris fermentation lysate filtrate is prepared from the discarded bacterial cells of the above-mentioned GS115-pPIC9K-COL3A1 engineered bacteria.
[0033] The sixth technical solution adopted by the present invention is a method for preparing a filtrate of a fermentation lysate of Pichia pastoris, wherein the filtrate of a fermentation lysate of Pichia pastoris is prepared by a high-pressure homogenization cell wall breaking method, wherein the cell concentration is 10% to 35% when the high-pressure homogenization cell wall breaking method is adopted, and cetearyl glucoside is added at a concentration of 1% to 3%;
[0034] When a high-pressure homogenizer is used to break the bacterial suspension, the homogenization temperature is 4-8°C and the homogenization pressure is 120 MPa. The lysate is obtained after one homogenization cycle. The lysate is centrifuged at a centrifugal force of 8000g to obtain a supernatant. In the clean area, the supernatant is sterilized and filtered through a 0.22μm hollow fiber membrane and a 0.22μm capsule filter in turn to obtain a Pichia fermentation lysate filtrate.
[0035] The seventh technical solution adopted by the present invention is that the Pichia pastoris fermentation lysate filtrate can be applied to the fields of beauty and skin care, and high-end medical beauty products. When the Pichia pastoris fermentation lysate filtrate is added in an amount of 2.5%, it has a significant firming and anti-wrinkle effect.
[0036] The beneficial effects of the present invention are:
[0037] (1) The humanized type III collagen engineering bacteria, expression vector, preparation method and application disclosed in the present invention belong to the microbial fermentation sub-field of synthetic biology; the present invention obtains an exocrine vector pPIC9K-COL3A1 through transformation, and the expression vector is transformed into the original bacteria of Pichia pastoris GS115 by conventional technical means. The GS115-pPIC9K-COL3A1 engineering bacteria obtained by screening has a higher promoter ability than the AOX1 promoter, and can effectively promote the exocrine expression of humanized type III collagen; the GS115-pPIC9K-COL3A1 engineering bacteria replaces the inherent methanol induction mode of the pPIC9K vector with a constitutive expression mode, that is, retains the original exocrine expression advantage of pPIC9K, and eliminates methanol, a toxic and harmful reagent, which is greener, safer, more environmentally friendly, and more convenient for engineering application;
[0038] (2) The amino acid sequence of humanized type III collagen produced by the technical means disclosed in the present invention is 100% homologous to the amino acid sequence of natural human collagen, has good functionality, tissue compatibility and safety, and the production method is green and safe, while greatly reducing the industrialization cost;
[0039] (3) The humanized type III collagen obtained by the present invention is a splicing of anti-degradation amino acid fragments screened by computer-assisted optimization, and has a stronger anti-degradation ability and a higher purity of more than 98.0%; the splicing of functional fragments that promote cell migration and repair screened by computer-assisted optimization has a stronger ability to promote cell repair, and the cell migration rate can reach 228.0%; the humanized type III collagen obtained by the present invention has both anti-degradation ability and efficient cell repair effect, and can be used in the fields of cosmetics and medical devices;
[0040] (4) After the engineered strain GS115-pPIC9K-COL3A1 prepared by the present invention is separated and purified to obtain humanized type III collagen, the residual bacteria are subjected to high-pressure homogenization, lysis, centrifugation, and filtration. The resulting Pichia pastoris fermentation lysate filtrate has antioxidant and soothing effects, as well as extremely significant firming, anti-wrinkle and barrier repair effects, and can be applied in the field of cosmetics. It can reuse discarded bacteria, reduce corporate costs, and kill two birds with one stone. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 This is the pPIC9K-COL3A1 plasmid map in Example 1 of the preparation method of the present invention;
[0042] Figure 2 This is the electrophoresis diagram of humanized type III collagen in Example 1 of the preparation method of the present invention;
[0043] Figure 3This is the spectrum of humanized type III collagen protein in Example 1 of the preparation method of the present invention;
[0044] Figure 4 is a bar graph of the cytotoxicity results in Example 1 of the preparation method of the present invention;
[0045] Figure 5 This is a diagram showing the cell migration results in Example 1 of the preparation method of the present invention;
[0046] Figure 6 is a bar graph of relative cell migration rates in Example 1 of the preparation method of the present invention;
[0047] Figure 7 is a bar graph of the cytotoxicity results in Example 2 of the preparation method of the present invention;
[0048] Figure 8 This is a graph showing changes in the levels of different genes regulated in Example 2 of the preparation method of the present invention;
[0049] Fig. 9 This is a diagram showing changes in the levels of different genes regulated in Example 2 of the preparation method of the present invention. DETAILED DESCRIPTION
[0050] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.
[0051] Humanized type III collagen engineering bacteria, the humanized type III collagen engineering bacteria is GS115-pPIC9K-COL3A1, which belongs to Pichia pastoris, and its Latin name is: Pichia pastoris. The strain is deposited in the General Microbiology Center of China Microorganism Culture Collection Administration, with the deposit number CGMCC No: 30003, and the deposit date is March 11, 2024. It solves the problem of introduction of methanol in the protein expression process of the prior art, which is prone to use risks or residues.
[0052] Specifically, the engineered bacteria GS115-pPIC9K-COL3A1 was obtained by transforming the expression vector pPIC9K-COL3A1 into the original strain of Pichia pastoris GS115 and then screening.
[0053] Humanized type III collagen, the amino acid sequence is shown in SEQ ID No. 1, and the nucleotide sequence is shown in SEQ ID No. 2. The amino acid sequence of humanized type III collagen is selected from 315-338aas, 354-374aas, 429-452aas, 459-476aas, 501-527aas, 540-575aas, 582-613aas, 647-686aas, 882-908aas, 921-944aas, 1023-1046aas, 1056-1094aas, 1161-1199aas on the a1 chain of the full-length humanized type III collagen, and is spliced sequentially from the N-terminus to the C-terminus to obtain a combined peptide chain of 375 amino acids;
[0054] The specific method for obtaining the expression vector pPIC9K-COL3A1 is as follows:
[0055] The pPIC9K vector was selected, and the Xho I site at 5708 bp was mutated from CTCGAG to CACGAG to obtain a point mutation pPIC9K vector;
[0056] The original strain of Pichia pastoris GS115 numbered CICC 33158 was selected, and the nucleotide sequence of 600 bp upstream of the aat promoter in the original strain and the Pichia pastoris a-Factor signal peptide sequence were spliced to form a grafted aat promoter, the sequence of which is shown in SEQ ID No. 3, a Pme I restriction endonuclease site was added to the 5' end of the sequence shown in SEQ ID No. 3, and an Xho I restriction endonuclease cleavage site was added to the 3' end, and the grafted aat promoter and the point-mutated pPIC9K vector were double-digested with Pme I and Xho I, respectively, and then connected to transform Escherichia coli for screening to obtain the modified pPIC9K vector;
[0057] An Xho I restriction endonuclease site was added to the 5' end of the sequence shown in SEQ ID No. 2, and an EcoR I restriction endonuclease site was added to the 3' end to obtain a COL3A1 nucleotide sequence, and the COL3A1 nucleotide sequence was fully synthesized; the fully synthesized COL3A1 nucleotide sequence and the modified pPIC9K vector were double-digested with Xho I and EcoR I, respectively, to obtain COL3A1 / X+E and modified pPIC9K / X+E, and then the two were connected and transformed into Escherichia coli competent cells, and the pPIC9K-COL3A1 expression vector was constructed and screened.
[0058] The preparation method of humanized type III collagen engineering bacteria, the engineering bacteria GS115-pPIC9K-COL3A1 is obtained by transforming the pPIC9K-COL3A1 expression vector into the original strain of Pichia pastoris GS115, and screening by histidine deficiency and G418 antibiotics, which solves the problem of easy degradation in the production process of collagen expression. The specific preparation method is as follows:
[0059] The obtained pPIC9K-COL3A1 plasmid was linearized with restriction endonuclease Sal I to obtain a pPIC9K-COL3A1 linearized plasmid, and the pPIC9K-COL3A1 linearized plasmid was transformed into Pichia pastoris GS115 competent cells, and histidine deficiency screening and 4 mg / mL G418 antibiotic screening were performed to obtain a positive clone GS115-pPIC9K-COL3A1 engineering strain;
[0060] The obtained GS115-pPIC9K-COL3A1 engineered strain was inoculated into BMGY medium for a shake flask experiment, glycerol was added, and it was naturally grown and expressed. The shake flask supernatant was collected for SDS-PAGE electrophoresis detection to screen out the GS115-pPIC9K-COL3A1 engineered bacteria that highly expressed humanized type III collagen.
[0061] The method for preparing the humanized type III collagen that can be produced is as follows: the humanized type III collagen is obtained by fermentation expression and purification of the above-mentioned engineering bacteria GS115-pPIC9K-COL3A1.
[0062] S1: protein fermentation: the GS115-pPIC9K-COL3A1 engineered strain was inoculated into BMGY medium for high-density fermentation. After the fermentation was completed, the supernatant was retained to obtain the fermentation supernatant containing humanized type III collagen;
[0063] The specific method is: the selected GS115-pPIC9K-COL3A1 engineered strain was inoculated into BMGY medium and cultured at 30°C with shaking until OD 600 When the pH reaches 9.8-10.3, the mixture is transferred to a fermentation tank filled with FBS medium, the temperature is kept constant at 28-30°C, the pH value is adjusted to 5.0-6.0 with ammonia water, the dissolved oxygen is controlled at 20-30%, and the fermentation is carried out for 90-100 hours. After the fermentation is completed, the fermentation liquid is centrifuged for solid-liquid separation, and the supernatant is retained to obtain the supernatant containing the target protein humanized type III collagen;
[0064] S2: Ultrafiltration concentration: Take the fermentation supernatant, centrifuge to remove the bacteria, filter using a 0.22um hollow fiber ultrafiltration membrane filter, ultrafiltration concentrate the supernatant to 20% of the original volume, remove inorganic salts in the ultrafiltration concentrate by gel filtration to obtain a desalted solution;
[0065] S3: treating the desalted liquid by ion exchange chromatography, collecting the eluate in sections and concentrating it;
[0066] S4: freeze-drying to obtain freeze-dried humanized type III collagen powder with a purity greater than 98.0%.
[0067] The humanized type III collagen prepared in the present application can be applied to the fields of beauty and skin care, high-end medical beauty products and medical devices.
[0068] The Pichia pastoris fermentation lysate filtrate is prepared from the discarded bacterial cells of the GS115-pPIC9K-COL3A1 engineered bacteria.
[0069] The method for preparing a filtrate of a fermentation lysate of Pichia pastoris comprises the following steps: the filtrate of a fermentation lysate of Pichia pastoris is prepared by a high-pressure homogenization cell wall breaking method, when the cell concentration is 10% to 35% by high-pressure homogenization cell wall breaking method, and cetearyl glucoside is added at a concentration of 1% to 3%;
[0070] When the bacterial suspension is broken by a high-pressure homogenizer, the homogenization temperature is 4-8°C and the homogenization pressure is 120MPa. After one homogenization cycle, the lysate is obtained. The lysate is centrifuged at a centrifugal force of 8000g to obtain the supernatant. In the clean area, the supernatant is sterilized and filtered through a 0.22μm hollow fiber membrane and a 0.22μm capsule filter in turn to obtain the Pichia fermentation lysate filtrate. This solves the problem of reusing discarded bacteria after the Pichia engineered bacteria produce humanized collagen.
[0071] The Pichia yeast fermentation lysate filtrate prepared in the present application is used in the fields of beauty and skin care, and high-end medical beauty products. When the Pichia yeast fermentation lysate filtrate is added in an amount of 2.5%, it has significant firming and anti-wrinkle effects.
[0072] Example 1
[0073] The preparation method of humanized type III collagen comprises the following specific steps:
[0074] Step 1: Obtaining the nucleotide sequence of humanized type III collagen
[0075] Preferably, 315-338aas, 354-374aas, 429-452aas, 459-476aas, 501-527aas, 540-575aas, 582-613aas, 647-686aas, 882-908aas, 921-944aas, 1023-1046aas, 1056-1094aas, 1161-1199aas on the a1 chain of full-length humanized type III collagen, totaling 375 amino acids, are spliced in sequence from N-terminus to C-terminus to obtain humanized type III collagen, the amino acid sequence is shown in SEQ ID No.1, and the nucleotide sequence is shown in SEQ ID No.2.
[0076] Step 2: Obtain pPIC9K-COL3A1 plasmid
[0077] The vector used in this technical route is the pPIC9K-COL3A1 vector. The specific steps to obtain it are as follows:
[0078] S1: The original pPIC9K vector was subjected to point mutation, and the Xho I site at 5708 bp was mutated from CTCGAG to CACGAG to obtain a point mutation pPIC9K vector.
[0079] S2: Select the nucleotide sequence of 600 bp upstream of the aat promoter in the original strain of Pichia pastoris GS115 (strain number CICC 33158) and the a-Factor signal peptide sequence of Pichia pastoris to form a grafted aat promoter, the sequence of which is shown in SEQ ID No. 3. Add a Pme I restriction endonuclease site at the 5' end of the sequence shown in SEQ ID No. 3, add an Xho I restriction endonuclease site at the 3' end, and perform double digestion of the grafted aat promoter and the point-mutated pPIC9K vector with Pme I and Xho I, respectively, and connect and transform Escherichia coli by conventional technical means in the art to obtain the modified pPIC9K vector for screening.
[0080] S3: Add an Xho I restriction endonuclease site to the 5' end of the sequence shown in SEQ ID No. 2, and add an EcoRI restriction endonuclease site to the 3' end to obtain the COL3A1 nucleotide sequence, and synthesize the COL3A1 nucleotide sequence by full gene synthesis.
[0081] S4: The synthesized COL3A1 nucleotide sequence and the modified pPIC9K vector were double-digested with Xho I and EcoR I, respectively, to obtain COL3A1 / X+E and the modified pPIC9K / X+E, and then the two were connected and transformed into competent E. coli by conventional technical means in the art, and the modified pPIC9K-COL3A1 plasmid was obtained by screening, such as Figure 1shown.
[0082] Step 3: Transformation screening and shake flask experiments
[0083] The pPIC9K-COL3A1 plasmid was linearized with restriction enzyme Sal I by conventional techniques in the art, transformed into Pichia pastoris GS115 competent cells, and subjected to histidine deficiency screening and 4 mg / mL G418 antibiotic screening to obtain a positive clone GS115-pPIC9K-COL3A1 engineered strain;
[0084] The GS115-pPIC9K-COL3A1 engineered strain was inoculated into BMGY medium for a shake flask experiment, supplemented with glycerol, and naturally grown and expressed. The supernatant of the shake flask was collected for SDS-PAGE electrophoresis detection. Figure 2 shown.
[0085] Step 4: Fermentation scale-up and protein purification
[0086] The selected GS115-pPIC9K-COL3A1 engineered strain was inoculated into 400 mL of BMGY medium and cultured at 29°C with shaking until OD 600 When the reaction mixture reaches 10, it is transferred to a 150L fermenter filled with FBS culture medium, the temperature is kept constant at 29°C, the pH is adjusted with ammonia water, and the pH is maintained at 5.0. The dissolved oxygen is controlled at 25% and the fermentation is carried out for 90 hours. After the fermentation is completed, the fermentation broth is separated into solid and liquid by centrifugation, and the supernatant is retained. The humanized type III collagen is present in the supernatant.
[0087] The fermentation supernatant was taken, centrifuged to remove the bacteria, filtered at 0.22um, and ultrafiltered to concentrate the supernatant to about 20% of the original volume. The desalted solution was desalted by a desalting column, and the desalted solution was treated by ion exchange chromatography. The eluate was collected in sections, concentrated and freeze-dried to obtain humanized type III collagen freeze-dried powder. The humanized type III collagen freeze-dried powder was subjected to mass spectrometry analysis, such as Figure 3 shown.
[0088] The various properties of the prepared humanized type III collagen were tested:
[0089] ① Cytotoxicity test
[0090] The cytotoxicity was detected by MTT method. Human fibroblasts (HSF) in logarithmic growth phase were cultured at 1.5×10 5Cells / mL were inoculated into a 96-well plate, 100 μL / well, and cultured for 24 hours; the drug was administered when the cell plating rate in the 96-well plate reached 40% to 60%. Sample group: 200 μL of culture medium containing different concentrations (10 mg / mL, 5 mg / mL, 2.5 mg / mL, 1.25 mg / mL, 0.625 mg / mL, 0.313 mg / mL, 0.156 mg / mL) of humanized type III collagen was added to each well; control group (SC): 200 μL of culture medium was added; blank group (BC): no cells, only 200 μL of culture medium was added; cultured for 24 hours. Abandon the liquid and replace it with culture medium containing MTT (0.5 mg / mL), 200 μL / well, and continue to culture for 4 hours. Abandon the liquid, add 150 μL / well of DMSO, shake thoroughly for color development, and detect OD with an enzyme reader. 490 , calculate the cell viability. If the cell viability is greater than 80%, it is considered to be non-cytotoxic, otherwise it is considered to be cytotoxic.
[0091] Cytotoxicity test results Figure 4 As shown, the humanized type III collagen provided by the present invention has no cytotoxicity when the concentration on HSF cells is not greater than 10 mg / mL;
[0092] ②Cell migration test
[0093] Human fibroblasts (HSF) in the logarithmic growth phase were cultured at 8×10 5 The cells were seeded into 6-well plates at a density of 100 cells / well and incubated in an incubator (37°C, 5% CO 2 ) and incubate overnight. When the plating rate reaches more than 70%, perform the scratch experiment. Use a 10uL gun tip to make two vertical scratches in the six-well plate. The vertical scratch is used as the baseline (the gun tip is perpendicular to the edge of the ruler), and the distance between the scratches is kept at 2cm; after making the vertical scratches, make horizontal scratches perpendicular to the baseline near the center axis of the six-well plate. After the scratches, wash the cells 3 times with PBS and administer the drug at concentrations (0.313mg / mL, 0.156mg / mL, 0.078mg / mL, 0.039mg / mL, 0.02mg / mL). The dosage per well is 2mL, and 2 replicate wells are set up for each group. Incubator (37°C, 5% CO 2 ) Continue to culture for 24 hours. Calculate the cell migration rate. The humanized type III collagen provided by the present invention has a cell migration rate of 228% at a concentration of 0.156 mg / mL, which has a significant repair effect. Figure 5 and Figure 6 .
[0094] Example 2
[0095] The preparation method of Pichia pastoris fermentation lysate filtrate comprises the following specific steps:
[0096] The Pichia pastoris cells obtained by centrifugation in step 3 of Example 1 were subjected to high-pressure homogenization and crushing.
[0097] The present invention selects a method combining cetearyl glucoside with high-pressure homogenization to break yeast cell walls, thereby increasing the concentration of homogenized bacterial suspension and also increasing the homogenization wall-breaking efficiency.
[0098] Weigh the wet yeast cells after fermentation centrifugation, add the above-mentioned cetearyl glucoside solution, stir and dissolve to obtain a yeast suspension containing 3% cetearyl glucoside and a cell concentration of 35%. Use a high-pressure homogenizer to break the bacterial suspension, control the homogenization temperature at 8°C and the homogenization pressure at 120MPa, and homogenize once to obtain a lysate. The lysate is centrifuged at a centrifugal force of 8000g to obtain a supernatant. In the clean area, the supernatant is sterilized and filtered through a 0.22μm hollow fiber membrane and a 0.22μm capsule filter in turn to obtain a Pichia fermentation lysate filtrate.
[0099] The various properties of the prepared Pichia pastoris fermentation lysate filtrate were tested:
[0100] ① Cytotoxicity test
[0101] The cytotoxicity was detected by MTT method. Human fibroblasts (HSF) in logarithmic growth phase were cultured at 1.5×10 5 Each well was inoculated with 100 μL / well of cells / mL into a 96-well plate and cultured for 24 hours. When the cell plating rate in the 96-well plate reached 40% to 60%, the drug was administered. Sample group: 200 μL of Pichia yeast fermentation lysate filtrate containing different concentrations (10%, 5%, 2.5%, 1.25%, 0.625%, 0.313%) was added to each well. Control group (SC): 200 μL of culture medium was added. Blank group (BC): no cells were added, only 200 μL of culture medium was added; cultured for 24 hours. Discard the liquid and replace it with a culture medium containing MTT (0.5 mg / mL), 200 μL / well, and continue to culture for 4 hours. Discard the liquid and add 150 μL / well of DMSO. After sufficient shaking and color development, the OD was detected using an enzyme reader. 490 , calculate the cell viability. If the cell viability is greater than 80%, it is considered to have no cytotoxic reaction, otherwise it is considered to have cytotoxic reaction.
[0102] Cytotoxicity test results Figure 7 As shown, the Pichia fermentation lysate filtrate provided by the present invention has no cytotoxicity when the concentration on HSF cells is not greater than 5%.
[0103] ② Antioxidant test
[0104] The fermentation lysate filtrate was subjected to DPPH free radical, ABTS free radical, hydroxyl free radical scavenging experiments and tyrosinase activity inhibition experiments with reference to GB / T 39100-2020 "DPPH and ABTS methods for the determination of antioxidant activity of polypeptides", Hu Ting et al. "Microwave preparation of mannuronic acid oligosaccharides and their in vitro antioxidant activity", and T / SHRH 015-2018 "Cosmetics-Tyrosinase activity inhibition test method". The results are shown in Table 1.
[0105] Table 1 Antioxidant test results of fermentation lysate filtrate
[0106] Dilution concentration 5% 2.5% DPPH removal rate / % 88.37±0.33 60.43±0.42 ABTS clearance rate / % 90.28±0.58 61.39±0.29 Hydroxyl free radical scavenging rate / % 81.53±0.41 56.25±0.53 Tyrosinase inhibition rate / % 96.31±0.95 69.61±0.62
[0107] When the dilution concentration of Pichia pastoris fermentation lysate filtrate was 5%, its DPPH / ABTS / hydroxyl radical scavenging rate was as high as over 80%, and the tyrosinase activity inhibition rate was 96.31%.
[0108] When the dilution concentration of the Pichia pastoris fermentation lysate filtrate was 2.5%, the DPPH / ABTS / hydroxyl free radical scavenging rate was above 55%, and the tyrosinase activity inhibition rate was 69.6%.
[0109] The Pichia yeast fermentation lysate filtrate provided by the invention can effectively remove free radicals, relieve skin oxidation and aging; can effectively inhibit tyrosinase activity, reduce melanin production, and whiten skin.
[0110] ③Gene level detection
[0111] Real-time fluorescence quantitative PCR was used. Human fibroblasts (HSF) in logarithmic growth phase were cultured at 6×10 5 The cells were seeded into 6-well plates at a density of 1000 cells / well and incubated in an incubator (37°C, 5% CO 2 ) and incubate overnight. When the cell plating rate in the 6-well plate reaches 40% to 50%, group dosing (5%, 2.5%) is performed, with a dosing volume of 2 mL per well and 1 well per group. After dosing, place the 6-well plate in an incubator (37°C, 5% CO 2 ) and incubated for 24 h. After the culture, the cells were washed three times with 2 mL / well PBS, and 1 mL RNAiso Plus was added to each well. After blowing and lysing the cells, the cell lysate was collected for RNA extraction, reverse transcription, and fluorescence quantitative PCR to detect the gene levels of COLⅠ, COLⅢ, COLIV, Elastin, LAMB3, Integrin-β, FLG, LOR, and PGC-1a. -△△Ct The relative expression of target genes was calculated by this method.
[0112] At a concentration of 2.5%, the filtrate of Pichia yeast fermentation lysate can significantly increase the expression levels of COLⅠ, COLⅢ, COLIV, Elastin, LAMB3, and Integrin-β genes, among which LAMB3 can be increased by about 14 times, with significant firming and anti-wrinkle effects. The results are shown in Figure 8 shown.
[0113] At a concentration of 5%, the filtrate of Pichia yeast fermentation lysate can significantly increase the expression levels of FLG, LOR, and PGC-1a genes, among which FLG and LOR can be increased by about 2 times, with significant moisturizing and barrier repair effects. The results are shown in Fig. 9 shown.
[0114] Example 3
[0115] The preparation method of humanized type III collagen is the same as that of Example 1, except that step 4: fermentation amplification and protein purification
[0116] The selected GS115-pPIC9K-COL3A1 engineered strain was inoculated into 400 mL of BMGY medium and cultured at 30 °C with shaking until OD 600 When the concentration reaches 10.3, it is transferred to a 150L fermenter filled with FBS culture medium, the temperature is kept constant at 30°C, the pH is adjusted with ammonia water, and the pH is maintained at 6.0. The dissolved oxygen is controlled at 30% and the fermentation is carried out for 100 hours. After the fermentation is completed, the fermentation broth is separated into solid and liquid by centrifugation, and the supernatant is retained. The humanized type III collagen is present in the supernatant.
[0117] Example 4
[0118] The preparation method of Pichia pastoris fermentation lysate filtrate is specifically as follows:
[0119] The Pichia pastoris cells obtained by centrifugation in step 3 of Example 1 were subjected to high-pressure homogenization and crushing.
[0120] The present invention selects a method combining cetearyl glucoside with high-pressure homogenization to break yeast cell walls, thereby increasing the concentration of homogenized bacterial suspension and also increasing the homogenization wall-breaking efficiency.
[0121] Weigh the wet yeast cells after fermentation centrifugation, add the above-mentioned cetearyl glucoside solution, stir and dissolve to obtain a yeast suspension containing 1% cetearyl glucoside and a cell concentration of 10%. Use a high-pressure homogenizer to break the bacterial suspension, control the homogenization temperature at 4°C and the homogenization pressure at 120MPa, and homogenize once to obtain a lysate. The lysate is centrifuged at a centrifugal force of 8000g to obtain a supernatant. In the clean area, the supernatant is sterilized and filtered through a 0.22μm hollow fiber membrane and a 0.22μm capsule filter in turn to obtain a Pichia fermentation lysate filtrate.
Claims
1. Humanized type III collagen engineered bacteria, characterized in that: The humanized type III collagen engineering bacteria is GS115-pPIC9K-COL3A1, which belongs to Pichia pastoris. The strain is deposited in the General Microbiology Center of China Microorganism Culture Collection Administration, with a deposit number of CGMCC No: 30003 and a deposit date of March 11, 2024; The engineered bacteria GS115-pPIC9K-COL3A1 is obtained by transforming the expression vector pPIC9K-COL3A1 into the original strain of Pichia pastoris GS115 and screening.
2. The humanized type III collagen engineering bacteria according to claim 1, characterized in that: The humanized type III collagen has an amino acid sequence as shown in SEQ ID No.1 and a nucleotide sequence as shown in SEQ ID No.
2. The amino acid sequence of the humanized type III collagen is selected from 315-338aas, 354-374aas, 429-452aas, 459-476aas, 501-527aas, 540-575aas, 582-613aas, 647-686aas, 882-908aas, 921-944aas, 1023-1046aas, 1056-1094aas, and 1161-1199aas on the a1 chain of the full-length humanized type III collagen, and is spliced sequentially from the N-terminus to the C-terminus to obtain a combined peptide chain of 375 amino acids.
3. The humanized type III collagen engineering bacteria according to claim 2, characterized in that: The specific method for obtaining the expression vector pPIC9K-COL3A1 is as follows: The pPIC9K vector was selected, and the Xho I site at 5708 bp was mutated from CTCGAG to CACGAG to obtain a point mutation pPIC9K vector; The original strain of Pichia pastoris GS115 numbered CICC 33158 was selected, and the nucleotide sequence of 600 bp upstream of the aat promoter in the original strain and the Pichia pastoris a-Factor signal peptide sequence were spliced to form a grafted aat promoter, the sequence of which is shown in SEQ ID No. 3, a Pme I restriction endonuclease site was added to the 5' end of the sequence shown in SEQ ID No. 3, and an Xho I restriction endonuclease cleavage site was added to the 3' end, and the grafted aat promoter and the point-mutated pPIC9K vector were double-digested with Pme I and Xho I, respectively, and then connected to transform Escherichia coli for screening to obtain the modified pPIC9K vector; An Xho I restriction endonuclease site was added to the 5' end of the sequence shown in SEQ ID No. 2, and an EcoR I restriction endonuclease site was added to the 3' end to obtain a COL3A1 nucleotide sequence, and the COL3A1 nucleotide sequence was fully synthesized; the fully synthesized COL3A1 nucleotide sequence and the modified pPIC9K vector were double-digested with Xho I and EcoR I, respectively, to obtain COL3A1 / X+E and modified pPIC9K / X+E, and then the two were connected and transformed into Escherichia coli competent cells, and the pPIC9K-COL3A1 expression vector was constructed and screened.
4. The method for preparing humanized type III collagen engineering bacteria according to claim 3, characterized in that: The engineered bacteria GS115-pPIC9K-COL3A1 was obtained by transforming the original strain of Pichia pastoris GS115 and screening by histidine deficiency and G418 antibiotic screening. The specific method is as follows: The obtained pPIC9K-COL3A1 plasmid was linearized with restriction endonuclease Sal I to obtain a pPIC9K-COL3A1 linearized plasmid, and the pPIC9K-COL3A1 linearized plasmid was transformed into Pichia pastoris GS115 competent cells, and histidine deficiency screening and 4 mg / mL geneticin screening were performed to obtain a positive clone GS115-pPIC9K-COL3A1 engineering strain; The obtained GS115-pPIC9K-COL3A1 engineered strain was inoculated into BMGY medium for a shake flask experiment, glycerol was added, and it was naturally grown and expressed. The shake flask supernatant was collected for SDS-PAGE electrophoresis detection to screen out the GS115-pPIC9K-COL3A1 engineered bacteria that highly expressed humanized type III collagen.
5. A method for preparing humanized type III collagen, characterized in that: The humanized type III collagen is obtained by fermentation expression and purification of the engineering bacteria GS115-pPIC9K-COL3A1 described in claim 1, and the specific steps are as follows: S1: protein fermentation: the GS115-pPIC9K-COL3A1 engineered strain was inoculated into BMGY medium for high-density fermentation. After the fermentation was completed, the supernatant was retained to obtain the fermentation supernatant containing humanized type III collagen; S2: Ultrafiltration concentration: Take the fermentation supernatant, centrifuge to remove the bacteria, filter using a 0.22um hollow fiber ultrafiltration membrane filter, ultrafiltration concentrate the supernatant to 20% of the original volume, remove inorganic salts in the ultrafiltration concentrate by gel filtration to obtain a desalted solution; S3: treating the desalted liquid by ion exchange chromatography, collecting the eluate in sections and concentrating it; S4: freeze-drying to obtain freeze-dried humanized type III collagen powder with a purity greater than 98.0%.
6. The method for preparing humanized type III collagen according to claim 5, characterized in that: The specific method of S1 is: inoculate the screened GS115-pPIC9K-COL3A1 engineered strain into BMGY medium, and culture with shaking at 30°C until OD 600 When the pH reaches 9.8-10.3, the culture medium is transferred to a fermentation tank filled with FBS culture medium, the temperature is kept constant at 28-30°C, the pH value is adjusted to 5.0-6.0 with ammonia water, the dissolved oxygen is controlled at 20-30%, and the fermentation is carried out for 90-100 hours. After the fermentation is completed, the fermentation broth is separated into solid and liquid by centrifugation, and the supernatant is retained to obtain the supernatant containing the target protein humanized type III collagen.
7. The humanized type III collagen according to claim 5 or 6 can be used in the fields of beauty and skin care, high-end medical beauty products and medical devices.
8. A filtrate of a Pichia pastoris fermentation lysate, characterized in that: The Pichia pastoris fermentation lysate filtrate is prepared from discarded bacterial cells of the GS115-pPIC9K-COL3A1 engineered bacteria described in claim 1.
9. The method for preparing the Pichia pastoris fermentation lysate filtrate according to claim 8, characterized in that: The specific method is as follows: the Pichia yeast fermentation lysate filtrate is prepared by a high-pressure homogenization cell wall breaking method, when the high-pressure homogenization cell wall breaking is adopted, the cell concentration is 10% to 35%, and the concentration of 1% to 3% of cetearyl glucoside is added; When a high-pressure homogenizer is used to break the bacterial suspension, the homogenization temperature is 4-8°C and the homogenization pressure is 120 MPa. The lysate is obtained after one homogenization cycle. The lysate is centrifuged at a centrifugal force of 8000g to obtain a supernatant. In the clean area, the supernatant is sterilized and filtered through a 0.22μm hollow fiber membrane and a 0.22μm capsule filter in turn to obtain a Pichia fermentation lysate filtrate.
10. The Pichia fermentation lysate filtrate according to claim 9 is used in the fields of beauty and skin care, and high-end medical beauty products. When the Pichia fermentation lysate filtrate is added in an amount of 2.5%, it has significant firming and anti-wrinkle effects.
Citation Information
Cited By
Preparation method and application of humanized III-type collagen
CN119708208A
Epidermal growth factor connecting polypeptide and application thereof in endometrial injury repair
CN119708267A
Recombinant type vii collagen having skin-whitening effect, preparation method therefor and use thereof
WO2026119282A1
